 Toby Trujillo
Concepts (215)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anticoagulants | 22 | 2023 | 748 | 3.010 |
Why?
| | Venous Thromboembolism | 17 | 2025 | 328 | 2.650 |
Why?
| | Factor Xa Inhibitors | 7 | 2025 | 194 | 1.520 |
Why?
| | Acute Coronary Syndrome | 4 | 2020 | 297 | 1.270 |
Why?
| | Hemorrhage | 10 | 2022 | 822 | 1.010 |
Why?
| | Practice Guidelines as Topic | 7 | 2025 | 1582 | 0.960 |
Why?
| | Thrombosis | 6 | 2023 | 400 | 0.950 |
Why?
| | Platelet Aggregation Inhibitors | 3 | 2023 | 499 | 0.900 |
Why?
| | Coronary Disease | 2 | 2025 | 382 | 0.880 |
Why?
| | Students, Pharmacy | 2 | 2016 | 96 | 0.840 |
Why?
| | Pharmacy Residencies | 2 | 2014 | 10 | 0.830 |
Why?
| | Potentially Inappropriate Medication List | 1 | 2023 | 17 | 0.800 |
Why?
| | Education, Pharmacy | 2 | 2016 | 120 | 0.790 |
Why?
| | Blood Coagulation | 4 | 2021 | 274 | 0.760 |
Why?
| | Geriatrics | 1 | 2023 | 95 | 0.730 |
Why?
| | Disease Management | 2 | 2025 | 653 | 0.690 |
Why?
| | Percutaneous Coronary Intervention | 2 | 2020 | 549 | 0.670 |
Why?
| | Warfarin | 3 | 2022 | 179 | 0.650 |
Why?
| | Piperazines | 4 | 2019 | 375 | 0.640 |
Why?
| | Atrial Fibrillation | 4 | 2022 | 558 | 0.640 |
Why?
| | Blood Coagulation Factors | 1 | 2020 | 71 | 0.600 |
Why?
| | Factor Xa | 4 | 2021 | 36 | 0.570 |
Why?
| | Vitamin K | 1 | 2019 | 46 | 0.570 |
Why?
| | Rivaroxaban | 8 | 2025 | 271 | 0.560 |
Why?
| | Blood Coagulation Disorders | 1 | 2020 | 198 | 0.550 |
Why?
| | Angina Pectoris | 2 | 2007 | 76 | 0.520 |
Why?
| | Acetanilides | 2 | 2007 | 11 | 0.510 |
Why?
| | Dalteparin | 2 | 2014 | 10 | 0.500 |
Why?
| | Fibrinolytic Agents | 2 | 2014 | 297 | 0.460 |
Why?
| | Thrombocytopenia | 2 | 2014 | 204 | 0.440 |
Why?
| | Thiophenes | 2 | 2014 | 117 | 0.420 |
Why?
| | Morpholines | 2 | 2014 | 130 | 0.420 |
Why?
| | Antithrombins | 4 | 2020 | 71 | 0.420 |
Why?
| | Patient-Centered Care | 2 | 2016 | 547 | 0.410 |
Why?
| | Recombinant Proteins | 6 | 2021 | 1368 | 0.410 |
Why?
| | Cardiovascular Diseases | 5 | 2023 | 2191 | 0.400 |
Why?
| | Enzyme Inhibitors | 2 | 2007 | 821 | 0.390 |
Why?
| | Humans | 55 | 2025 | 145783 | 0.370 |
Why?
| | Secondary Prevention | 2 | 2025 | 251 | 0.350 |
Why?
| | Administration, Oral | 7 | 2022 | 867 | 0.340 |
Why?
| | Arginine | 5 | 2020 | 264 | 0.320 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 2010 | 156 | 0.300 |
Why?
| | Pyridones | 5 | 2021 | 209 | 0.290 |
Why?
| | Fibrinolysis | 1 | 2010 | 164 | 0.280 |
Why?
| | Myocardial Infarction | 2 | 2020 | 1211 | 0.270 |
Why?
| | Chronic Disease | 4 | 2025 | 1812 | 0.270 |
Why?
| | Electric Countershock | 2 | 2019 | 126 | 0.270 |
Why?
| | Arrhythmias, Cardiac | 1 | 2010 | 356 | 0.260 |
Why?
| | Pyrazoles | 5 | 2021 | 517 | 0.250 |
Why?
| | Heparin | 4 | 2016 | 247 | 0.250 |
Why?
| | Angina, Stable | 1 | 2006 | 18 | 0.240 |
Why?
| | Cyclooxygenase 2 Inhibitors | 1 | 2006 | 24 | 0.240 |
Why?
| | Thrombin | 2 | 2020 | 172 | 0.240 |
Why?
| | Drug Interactions | 5 | 2016 | 405 | 0.230 |
Why?
| | Aged | 14 | 2025 | 26217 | 0.230 |
Why?
| | Pharmacists | 3 | 2014 | 258 | 0.220 |
Why?
| | Sucrose | 1 | 2005 | 114 | 0.210 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2020 | 1752 | 0.210 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2005 | 133 | 0.210 |
Why?
| | Thromboembolism | 2 | 2016 | 129 | 0.200 |
Why?
| | Diet | 1 | 2012 | 1278 | 0.200 |
Why?
| | Pipecolic Acids | 3 | 2020 | 26 | 0.200 |
Why?
| | Dabigatran | 4 | 2016 | 30 | 0.200 |
Why?
| | Hirudins | 3 | 2020 | 53 | 0.200 |
Why?
| | Inappropriate Prescribing | 1 | 2023 | 66 | 0.190 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2019 | 992 | 0.170 |
Why?
| | Aged, 80 and over | 5 | 2025 | 8347 | 0.170 |
Why?
| | Antiphospholipid Syndrome | 1 | 2021 | 37 | 0.170 |
Why?
| | Coronary Artery Disease | 1 | 2007 | 750 | 0.170 |
Why?
| | Prothrombin | 1 | 2021 | 25 | 0.170 |
Why?
| | Middle Aged | 11 | 2025 | 36309 | 0.160 |
Why?
| | Pharmaceutical Services | 2 | 2013 | 76 | 0.160 |
Why?
| | Aspirin | 2 | 2023 | 406 | 0.160 |
Why?
| | Drug-Eluting Stents | 1 | 2020 | 88 | 0.150 |
Why?
| | Male | 17 | 2025 | 73010 | 0.150 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2000 | 144 | 0.150 |
Why?
| | Peptide Fragments | 3 | 2020 | 697 | 0.150 |
Why?
| | Stroke | 2 | 2022 | 1271 | 0.150 |
Why?
| | Hospitalization | 3 | 2025 | 2461 | 0.150 |
Why?
| | Intracranial Hemorrhages | 1 | 2020 | 106 | 0.150 |
Why?
| | Chi-Square Distribution | 1 | 2020 | 528 | 0.150 |
Why?
| | Female | 17 | 2025 | 79045 | 0.140 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2020 | 138 | 0.140 |
Why?
| | Electrodiagnosis | 1 | 2018 | 17 | 0.140 |
Why?
| | Communication | 2 | 2016 | 977 | 0.140 |
Why?
| | Blood Coagulation Tests | 2 | 2016 | 72 | 0.140 |
Why?
| | Neoplasms | 1 | 2014 | 2913 | 0.140 |
Why?
| | Goals | 1 | 2020 | 185 | 0.140 |
Why?
| | Adult | 10 | 2025 | 40881 | 0.130 |
Why?
| | Obesity, Morbid | 1 | 2022 | 293 | 0.130 |
Why?
| | Drug Therapy, Combination | 1 | 2020 | 1043 | 0.130 |
Why?
| | Ranolazine | 2 | 2007 | 23 | 0.130 |
Why?
| | Acute Kidney Injury | 1 | 2005 | 874 | 0.130 |
Why?
| | Retrospective Studies | 8 | 2022 | 17330 | 0.130 |
Why?
| | Partial Thromboplastin Time | 2 | 2014 | 53 | 0.120 |
Why?
| | Critical Illness | 1 | 2023 | 900 | 0.120 |
Why?
| | Electrocardiography | 2 | 2010 | 668 | 0.120 |
Why?
| | Clinical Trials as Topic | 2 | 2012 | 1062 | 0.120 |
Why?
| | Healthcare Disparities | 2 | 2014 | 736 | 0.120 |
Why?
| | Heart-Assist Devices | 1 | 2021 | 568 | 0.110 |
Why?
| | Catheter Ablation | 1 | 2019 | 355 | 0.110 |
Why?
| | United States | 5 | 2020 | 16126 | 0.100 |
Why?
| | Medicare | 1 | 2020 | 904 | 0.100 |
Why?
| | Blood Loss, Surgical | 1 | 2014 | 114 | 0.100 |
Why?
| | Venous Thrombosis | 1 | 2016 | 196 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2016 | 2028 | 0.100 |
Why?
| | Educational Measurement | 1 | 2016 | 326 | 0.100 |
Why?
| | Postoperative Hemorrhage | 1 | 2014 | 105 | 0.100 |
Why?
| | Pulmonary Embolism | 1 | 2016 | 241 | 0.100 |
Why?
| | Hip Joint | 1 | 2014 | 173 | 0.090 |
Why?
| | Emergency Treatment | 1 | 2013 | 123 | 0.090 |
Why?
| | Treatment Outcome | 5 | 2020 | 11794 | 0.090 |
Why?
| | History, 21st Century | 1 | 2013 | 222 | 0.090 |
Why?
| | Glycemic Index | 1 | 2012 | 26 | 0.090 |
Why?
| | Edible Grain | 1 | 2012 | 47 | 0.090 |
Why?
| | Diet, Sodium-Restricted | 1 | 2012 | 38 | 0.090 |
Why?
| | Perioperative Care | 2 | 2014 | 231 | 0.090 |
Why?
| | Diet, Fat-Restricted | 1 | 2012 | 79 | 0.090 |
Why?
| | Diet, Carbohydrate-Restricted | 1 | 2012 | 38 | 0.090 |
Why?
| | Diet, Mediterranean | 1 | 2012 | 27 | 0.090 |
Why?
| | History, 20th Century | 1 | 2013 | 328 | 0.090 |
Why?
| | Dietary Fiber | 1 | 2012 | 59 | 0.090 |
Why?
| | Surgical Procedures, Operative | 1 | 2014 | 271 | 0.090 |
Why?
| | Forecasting | 1 | 2013 | 390 | 0.080 |
Why?
| | Fruit | 1 | 2012 | 146 | 0.080 |
Why?
| | Empirical Research | 1 | 2011 | 21 | 0.080 |
Why?
| | Vegetables | 1 | 2012 | 162 | 0.080 |
Why?
| | Blood Transfusion | 1 | 2014 | 409 | 0.080 |
Why?
| | Risk Factors | 2 | 2020 | 10919 | 0.080 |
Why?
| | Dietary Proteins | 1 | 2012 | 135 | 0.080 |
Why?
| | Clinical Competence | 2 | 2016 | 1247 | 0.080 |
Why?
| | Research | 1 | 2014 | 431 | 0.080 |
Why?
| | Nomograms | 1 | 2011 | 59 | 0.080 |
Why?
| | Self Care | 1 | 2013 | 392 | 0.080 |
Why?
| | Polysaccharides | 1 | 2010 | 86 | 0.080 |
Why?
| | Insurance Coverage | 1 | 2011 | 244 | 0.080 |
Why?
| | Curriculum | 1 | 2016 | 1074 | 0.070 |
Why?
| | Time Factors | 1 | 2020 | 7134 | 0.070 |
Why?
| | Life Style | 1 | 2012 | 486 | 0.070 |
Why?
| | Pharmacy Service, Hospital | 1 | 2010 | 89 | 0.070 |
Why?
| | Complementary Therapies | 1 | 2010 | 96 | 0.070 |
Why?
| | Patient Care Team | 1 | 2014 | 697 | 0.070 |
Why?
| | Colonic Neoplasms | 1 | 2010 | 258 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2016 | 1420 | 0.070 |
Why?
| | Thrombin Time | 2 | 2020 | 13 | 0.070 |
Why?
| | Myocardial Revascularization | 1 | 2007 | 85 | 0.060 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2010 | 183 | 0.060 |
Why?
| | Job Satisfaction | 1 | 2010 | 238 | 0.060 |
Why?
| | Sulfonamides | 3 | 2020 | 583 | 0.060 |
Why?
| | Patient Acceptance of Health Care | 1 | 2014 | 883 | 0.060 |
Why?
| | Delayed-Action Preparations | 1 | 2007 | 189 | 0.060 |
Why?
| | Bariatric Surgery | 1 | 2010 | 253 | 0.060 |
Why?
| | Prostaglandins | 1 | 2006 | 94 | 0.060 |
Why?
| | Academic Medical Centers | 2 | 2020 | 554 | 0.060 |
Why?
| | Kidney Diseases | 1 | 2010 | 426 | 0.060 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2006 | 93 | 0.060 |
Why?
| | Surveys and Questionnaires | 2 | 2016 | 6085 | 0.060 |
Why?
| | Long QT Syndrome | 1 | 2006 | 68 | 0.060 |
Why?
| | Intensive Care Units | 2 | 2023 | 924 | 0.060 |
Why?
| | Excipients | 1 | 2005 | 55 | 0.060 |
Why?
| | Chemistry, Pharmaceutical | 1 | 2005 | 112 | 0.050 |
Why?
| | beta-Alanine | 2 | 2014 | 25 | 0.050 |
Why?
| | Animals | 5 | 2019 | 38101 | 0.050 |
Why?
| | Acute Disease | 2 | 2014 | 1036 | 0.050 |
Why?
| | Thromboxane B2 | 1 | 2023 | 23 | 0.050 |
Why?
| | Obesity | 2 | 2023 | 3118 | 0.050 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 346 | 0.050 |
Why?
| | Benzimidazoles | 2 | 2014 | 189 | 0.050 |
Why?
| | Healthy Volunteers | 1 | 2023 | 219 | 0.040 |
Why?
| | Thinness | 1 | 2022 | 100 | 0.040 |
Why?
| | Prospective Studies | 2 | 2025 | 8078 | 0.040 |
Why?
| | Pharmacokinetics | 1 | 2000 | 33 | 0.040 |
Why?
| | Thrombelastography | 1 | 2021 | 192 | 0.040 |
Why?
| | Professional Role | 2 | 2013 | 170 | 0.040 |
Why?
| | Aftercare | 1 | 2022 | 222 | 0.040 |
Why?
| | Disease Progression | 1 | 2007 | 2865 | 0.040 |
Why?
| | Allied Health Personnel | 1 | 2020 | 53 | 0.040 |
Why?
| | Infusions, Intravenous | 1 | 2020 | 428 | 0.040 |
Why?
| | Hemostasis | 1 | 2019 | 98 | 0.030 |
Why?
| | Syndrome | 1 | 1998 | 381 | 0.030 |
Why?
| | Critical Care | 1 | 2023 | 702 | 0.030 |
Why?
| | Body Weight | 1 | 2021 | 972 | 0.030 |
Why?
| | Cohort Studies | 2 | 2021 | 6033 | 0.030 |
Why?
| | Young Adult | 2 | 2025 | 14254 | 0.030 |
Why?
| | Hospitals | 1 | 2022 | 733 | 0.030 |
Why?
| | Heart Failure | 1 | 2010 | 2326 | 0.030 |
Why?
| | Risk Assessment | 1 | 2006 | 3752 | 0.030 |
Why?
| | Calibration | 1 | 2016 | 152 | 0.030 |
Why?
| | Thiazoles | 1 | 2016 | 142 | 0.030 |
Why?
| | Quality of Life | 1 | 2007 | 3211 | 0.030 |
Why?
| | Patient Discharge | 1 | 2022 | 995 | 0.030 |
Why?
| | Thromboplastin | 1 | 2014 | 67 | 0.030 |
Why?
| | Body Mass Index | 1 | 2023 | 2447 | 0.030 |
Why?
| | Clinical Protocols | 1 | 2014 | 280 | 0.020 |
Why?
| | Incidence | 1 | 2019 | 2934 | 0.020 |
Why?
| | Pyridines | 1 | 2016 | 609 | 0.020 |
Why?
| | Medically Uninsured | 1 | 2011 | 132 | 0.020 |
Why?
| | Drug Monitoring | 1 | 2014 | 401 | 0.020 |
Why?
| | Continuity of Patient Care | 1 | 2013 | 297 | 0.020 |
Why?
| | Pharmacy Administration | 1 | 2010 | 1 | 0.020 |
Why?
| | Societies, Pharmaceutical | 1 | 2010 | 14 | 0.020 |
Why?
| | Health Care Costs | 1 | 2013 | 425 | 0.020 |
Why?
| | Career Mobility | 1 | 2010 | 68 | 0.020 |
Why?
| | Micronutrients | 1 | 2010 | 102 | 0.020 |
Why?
| | Evidence-Based Medicine | 1 | 2013 | 740 | 0.020 |
Why?
| | Awards and Prizes | 1 | 2010 | 71 | 0.020 |
Why?
| | Food | 1 | 2010 | 150 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2013 | 587 | 0.020 |
Why?
| | Reward | 1 | 2010 | 248 | 0.020 |
Why?
| | Patient Readmission | 1 | 2011 | 773 | 0.010 |
Why?
| | Length of Stay | 1 | 2011 | 1350 | 0.010 |
Why?
| | Dietary Supplements | 1 | 2010 | 584 | 0.010 |
Why?
| | Motivation | 1 | 2010 | 602 | 0.010 |
Why?
| | Adolescent | 1 | 2025 | 22577 | 0.010 |
Why?
| | Internet | 1 | 2010 | 693 | 0.010 |
Why?
|
|
Trujillo's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|